State Street Holds 5.4% Of Collegium — It Has No Plan To Influence Control

The passive holding comes as ADHD-drug sales grow, generic competition cuts pain revenue and quarterly profit falls.

Share
State Street Holds 5.4% Of Collegium — It Has No Plan To Influence Control

State Street reported a 5.4% passive stake in Collegium Pharmaceutical, which sells prescription medicines for ADHD and moderate to severe pain, in an SEC ownership filing Tuesday. The 1,772,243-share holding carries no purpose of changing or influencing control of the company.

A Stake Without A Control Agenda

State Street's holding was measured as of September 30, 2026. It reported shared voting power over 1,689,578 shares and zero shares over which it alone could vote.

The certification places the investment within State Street's ordinary business activity. It covers both how the securities were obtained and why they are held, rather than announcing an effort to direct Collegium's management.

ADHD Growth Meets Pain Competition

Collegium's third-quarter results put the business transition in numbers: Jornay PM sales reached $51.9 million, up 24%, which the company called a record. Nucynta revenue fell 44% with generic competition affecting the pain business.

Quarterly net income fell to $21.8 million from $31.5 million a year earlier. Growth in the ADHD treatment therefore accompanied lower overall profit.

Jornay PM is Collegium's ADHD medicine. Its pain portfolio includes Belbuca, Xtampza ER, Nucynta ER and Nucynta IR; Symproic treats opioid-related constipation. Third-party manufacturers produce the medicines, which Collegium sells in the United States mainly through wholesalers supplying retail pharmacies, managed health care organizations and government agencies.

Pain Cash Funds The ADHD Shift

Oppenheimer described Collegium's move from its mature pain business toward an ADHD-drug platform as self-funding. Truist pointed to durable cash flow from the pain portfolio as support for share repurchases and ADHD investment.

The company maintains separate sales teams for the businesses. Its annual report for 2025 described about 105 representatives and managers in pain, calling on about 10,000 health care professionals, and about 200 in ADHD, calling on about 21,000.

Collegium expects to finish its $50 million accelerated share repurchase program by year-end.

Sources

More on Collegium Pharmaceutical

All Collegium Pharmaceutical (COLL) coverage →